Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival by ten Haaf, Anette et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Expression of the glioma-associated oncogene homolog (GLI) 1 in 
human breast cancer is associated with unfavourable overall 
survival
Anette ten Haaf1, Nuran Bektas2, Sonja von Serenyi1, Inge Losen1, 
Elfriede Christel Arweiler3, Arndt Hartmann4, Ruth Knüchel1 and 
Edgar Dahl*1
Address: 1Molecular Oncology Group, Institute of Pathology, University Hospital of the RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, 
Germany, 2Institute of Pathology, University Hospital Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany, 3Institute of Medical Statistics, 
University Hospital of the RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany and 4Institute of Pathology, University Hospital Erlangen, 
Krankenhausstrasse 12, 91054 Erlangen, Germany
Email: Anette ten Haaf - atenhaaf@ukaachen.de; Nuran Bektas - Nuran.Bektas@ukb.uni-bonn.de; Sonja von 
Serenyi - svonserenyi@ukaachen.de; Inge Losen - ilosen@ukaachen.de; Elfriede Christel Arweiler - earweiler@ukaachen.de; 
Arndt Hartmann - arndt.hartmann@uk-erlangen.de; Ruth Knüchel - rknuechel-clarke@ukaachen.de; Edgar Dahl* - edahl@ukaachen.de
* Corresponding author    
Abstract
Background: The transcription factor GLI1, a member of the GLI subfamily of Krüppel-like zinc
finger proteins is involved in signal transduction within the hedgehog pathway. Aberrant hedgehog
signalling has been implicated in the development of different human tumour entities such as colon
and lung cancer and increased GLI1 expression has been found in these tumour entities as well. In
this study we questioned whether GLI1 expression might also be important in human breast cancer
development. Furthermore we correlated GLI1 expression with histopathological and clinical data
to evaluate whether GLI1 could represent a new prognostic marker in breast cancer treatment.
Methods: Applying semiquantitative realtime PCR analysis and immunohistochemistry (IHC) GLI1
expression was analysed in human invasive breast carcinomas (n = 229) in comparison to normal
human breast tissues (n = 58). GLI1 mRNA expression was furthermore analysed in a set of normal
(n = 3) and tumourous breast cell lines (n = 8). IHC data were statistically interpreted using SPSS
version 14.0.
Results: Initial analysis of GLI1 mRNA expression in a small cohort of (n = 5) human matched
normal and tumourous breast tissues showed first tendency towards GLI1 overexpression in
human breast cancers. However only a small sample number was included into these analyses and
values for GLI1 overexpression were statistically not significant (P = 0.251, two-tailed Mann-
Whitney U-test). On protein level, nuclear GLI1 expression in breast cancer cells was clearly more
abundant than in normal breast epithelial cells (P = 0.008, two-tailed Mann-Whitney U-test) and
increased expression of GLI1 protein in breast tumours significantly correlated with unfavourable
overall survival (P = 0.019), but also with higher tumour stage (P < 0.001) and an increased number
of tumour-positive axillar lymph nodes (P = 0.027). Interestingly, a highly significant correlation was
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found between GLI1 expression and the expression of SHH, a central upstream molecule of the
hedgehog pathway that was previously analysed on the same tissue microarray.
Conclusion: Our study presents a systematic expression analysis of GLI1 in human breast cancer.
Elevated levels of GLI1 protein in human breast cancer are associated with unfavourable prognosis
and progressive stages of disease. Thus GLI1 protein expression measured e.g. by an IHC based
scoring system might have an implication in future multi-marker panels for human breast cancer
prognosis or molecular sub typing. The highly significant correlation between SHH and GLI1
expression characterises GLI1 as a potential functional downstream target of the hedgehog
signalling pathway in human breast cancer as well. Furthermore, our study indicates that altered
hedgehog signalling may represent a key disease pathway in the progression of human breast
cancer.
Background
The hedgehog (Hh) signalling pathway is known to be
essential for multiple aspects of embryonic development.
It is implicated in processes of organ patterning, cell dif-
ferentiation and cell proliferation but it also plays a cru-
cial role in the development of the limb, lung, brain and
foregut [1]. An active involvement of Hh signalling has
been shown for a variety of human tumour entities
including tumours of skin, cerebellum, muscle, lung,
digestive tract, pancreas and prostate [2-7]. Furthermore,
the malignancy of tumours and their progression to met-
astatic stages have been associated with the activity of the
Hh signalling pathway [8,9]. GLI1 is a member of this
pathway and belongs to the family of GLI transcription
factors including GLI1, GLI2 and GLI3. These transcrip-
tion factors act as downstream mediators of Hh signalling
and they share in common a DNA binding zinc finger
domain [10]. The human GLI1 gene is located on chro-
mosome 12q13.2-q13.3 [11] and functions as an activa-
tor of transcription [12]. Downstream targets of GLI1
signalling include molecules with regulatory effects on
cell cycle and apoptosis such as Cyclin D2 or FOXM1 in
basal cell carcinomas [13,14]. Several studies on GLI1
analysed potential involvement of this transcription fac-
tor in tumour developmental processes. Dahmane et al.
(1997) [15] showed that ectopic expression of GLI1 in the
basal cells of the embryonic frog epidermis is able to
induce basal cell carcinomas. Additionally in human
oesophageal squamous cell carcinomas an association
was found between the expression of GLI1 and depth of
tumour invasion, status of lymph node metastasis, as well
as unfavourable overall survival [16].
SHH is another important member of the Hh signalling
cascade which acts upstream of GLI1 in the activation
process of the Hh pathway [17]. It binds to the receptor
Patched (PTCH) 1 or 2, which then relieves repression of
the membrane protein Smoothened (SMO), a G protein-
coupled receptor related protein [9,17]. The relief of SMO
inhibition leads to an activation of GLI1 [18]. As a result
of this GLI1 accumulates in the nucleus [19] where it con-
trols the expression of typical Hh target genes [20]. Thus
SHH expression is assumed to have a direct impact on
GLI1 activity. A significant correlation between increased
expression of both SHH and GLI1 in human breast cancer
would support the hypothesis that aberrant Hh signalling
contributes to breast cancer development or progression.
Therefore we performed a systematic expression analysis
of GLI1 in human breast cancer on the mRNA and protein
level and correlated GLI1 expression with clinicopatho-
logical patient characteristics. Subsequently we compared
GLI1 expression data to previous data on the expression of
SHH in the same collective of breast tumours.
Methods
Patient samples and breast cancer tissue microarray 
(TMA)
Samples of tumourous and normal breast tissues were
derived from patients that underwent primary surgery for
breast cancer at the Departments of Gynaecology at the
University Hospitals of Aachen and Regensburg. All
patients gave informed consent for retention and analysis
of their tissue for research purposes and the Institutional
Review Board of the participating centre approved the
study.
Tissues were immediately snap-frozen in liquid nitrogen.
To determine the percentage of tumour cells H&E staining
was carried out on sections of each tissue. Only samples
that contained more than 70% tumour cells were selected
for further analysis. In order to determine the precise ratio
of cancer cells the dissected tumours were macroscopi-
cally and microscopically (high power field; ×400) exam-
ined by a team of experienced pathologists.
Clinicopathological characteristics of the tumours are
listed in Table 1. GLI1 expression was further analysed by
immunohistochemistry on a breast cancer TMA contain-
ing 204 breast cancer specimens and 46 normal breast tis-
sue specimens. This TMA has previously been described in
detail [21]. In short, tissue cores on the TMA were derived
from non-selected, formalin-fixed and paraffin-embed-
ded primary breast cancer specimens that had been diag-BMC Cancer 2009, 9:298 http://www.biomedcentral.com/1471-2407/9/298
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nosed at the Institute of Pathology, University of
Regensburg, Germany between 1994 and 2002. Prior to
construction of the TMA haematoxylin and eosin (H&E)
staining was carried out to identify representative tumour
areas. Slides for all specimens were evaluated with help of
an experienced surgical pathologist (A.H.) and tumour
grades were predicted on basis of the Elston and Ellis grad-
ing definitions [22]. Amplification of the HER2 gene in
tumours with a medium HER2 staining intensity of "score
2" was tested by additional FISH analyses in order to
determine HER2 amplification of these tumours. As 62%
of the analysed tumours were negative for HER2  gene
amplification they were included into the group of HER
"weak expressers" (0–2+ (weak) vs. 3+ (strong)). Tissues
on the TMA were derived from patients with a median age
of 56 years (range from 25 to 82 years). All clinical follow-
up data were derived from the Central Tumour Registry,
Regensburg, Germany with a median follow-up period of
78 months (range 0–148 months). Both studies were
approved by the Institutional Review Board of each partic-
ipating centre and all patients agreed to retention and
analysis of their tissues for research purposes.
Cell lines
The human mammary epithelial cell lines HMEC,
MCF12A and MCF10A as well as the breast cancer cell
lines T47D, MCF7, ZR75-1, SKBR3, MDA-MB468, BT20,
MDA-MB231 and MDA-MB435s were obtained from the
ATCC (Rockville, MD, USA) and cultured as previously
described [23].
DNA and RNA extraction and reverse transcription
For DNA extractions tissue samples were lysed overnight
at a temperature of 56°C with 800 rpm shaking. After 12
h incubation time DNA was isolated according to the
instructions of the blood and cell culture DNA kit (Qia-
gen, Hilden, Germany). RNA was extracted following the
manufacturer's protocols for Trizol isolation (Invitrogen,
CA). For RNA extractions from paraffin-embedded tissues
representative sections were determined, deparaffinised
and conventionally rehydrated in a decreasing alcohol-
series prior to extraction. Using the Reverse Transcription
System (Promega Corporation, WI) cDNA was synthe-
sised using 1 μg of each RNA.
Semiquantitative realtime PCR
The IQ™5 realtime PCR Detection System was used. All
reactions consisted of 10 μM forward primer, 10 μM
reverse primer, 10 μl iQ™ SYBR® Green Supermix (Bio-Rad
Laboratories, Munich, Germany) and 1–2 μl of cDNA as
PCR template in a final reaction volume of 20 μl. Gene
expression was quantified using the comparative CT
method, which normalises the CT values to an internal
housekeeping gene (GAPDH) and calculates the relative
expression values [24]. Primer sequences for GLI1  and
GAPDH are listed in Table 2. The cycling conditions were
set up to an initial denaturation step at 95°C for 3 min,
followed by 43 cycles with denaturation at 95°C for 15 s,
annealing of the primers at 65°C for 15 s and elongation
at 72°C for 20 s. Melting curve analyses as well as gel elec-
trophoretical analyses were performed to verify the specif-
icity of the PCR products. To ensure accuracy of the results
all reactions were performed in triplicate and arithmetic
means were represented for each sample.
GLI1 immunohistochemistry
Immunohistochemical analysis of the TMA was carried
out according to the manufacturer's instructions (Advance
Table 1: Clinicopathological characteristics of primary breast carcinomas (n = 5)
Tumour Nr. Histological type Tumour stagea
(pT)
Lymph node status
(pN)
Histological grade
(G)
T1 ductal pT1 pN0 G3
T2 ductal pT2 pN1 G3
T3 ductal pT1 pN1 G3
T4 ductal pT2 pN1 G3
T5 ductal pT3 pN3 G2
aAccording to UICC: TNM Classification of Malignant Tumours. 6th edn (2002) Sobin LH, Wittekind CH (eds) Wiley: New York
Table 2: Primer sequences and annealing temperatures used in this study
Sequence Annealing temperature (°C)
Semiquantitative Realtime PCR (Light Cycler)
GLI1 Forward: 5'- AGGGAGTGCAGCCAATACAG -3'
Reverse: 5'- ATTGGCCGGAGTTGATGTAG -3'
65
GAPDH Forward: 5'- GAAGGTGAAGGTCGGAGTCA -3'
Reverse: 5'- AATGAAGGGGTCATTGATGG -3'
65BMC Cancer 2009, 9:298 http://www.biomedcentral.com/1471-2407/9/298
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Kit, DAKO K4068, Glostrup, Denmark). Tissues were
deparaffinised and rehydrated followed by a microwave
heating for 30 min in 10 mM sodium citrate buffer (pH
7.2). Peroxidase blocking solution (DAKO S 2023) was
used for blocking of endogenous peroxidises. The polyclo-
nal primary antibody GLI1 (Santa Cruz sc-20687, CA) was
applied (1:50 dilution) overnight at 4°C. Sections from
human basal cell carcinoma in which GLI1 expression has
already been described by Ghali et al. (1999) served as
positive controls. The application of primary antibodies
to tissue sections was omitted in negative controls. Signals
were developed in a 30 min incubation step with the
Advance Kit HRP against rabbit/mouse (DakoCytomation
K4065) followed by 3,3'-Diaminobenzidine (DAB) detec-
tion. Slides were counterstained with haematoxylin and
after dehydration mounted in Vitro-Clud (Langenbrinck,
Emmendingen, Germany). Intensity and scoring of the
immunohistochemical staining was determined through
an experienced pathologist (N.B.) following instructions
of the scoring system suggested by Remmele and Stegner
[25].
The Immuno-Reactive-Score (IRS) is product of staining
intensity (graded between negative = 0 and strong = 3)
and the percentage of positively stained cells (graded
between 0 and 4, being 1 = <25%, 2 = 25–50%; 3 = 51–
75%, and 4 = >75%, respectively). Cases with discrepan-
cies in IRS score were discussed together with other
pathologists until consensus was reached.
Statistics
Immunohistochemical data were statistically analysed
using the SPSS software version 14.0 (SPSS GmbH Soft-
ware, Munich, Germany). Differences with a p-value <
0.05 were defined to be statistically significant. A non-par-
ametrically two-tailed Mann-Whitney U-test was used for
determination of differences in the GLI1 expression levels.
Additionally a two-sided Fisher's exact test was performed
to analyse possible associations between GLI1 expression
and clinicopathological parameters. Logistic regression
analysis included all parameters that were significantly
prognostic in univariate analysis at a level of P < 0.2. Ear-
lier studies from our group analysed the protein expres-
sion of Hh member SHH on the same set of tissues
specimens. The results from these analyses were used in a
second Fisher's exact test to compare the levels of protein
expression for the two Hh members SHH and GLI1 in
normal breast and tumourous breast tissues. Overall sur-
vival (OS) and Recurrence-free (RFS) were calculated in
accordance with the Kaplan-Meier equation.
Results
GLI1 mRNA expression in cancerous human epithelial 
breast cell lines
Our study was initiated by a GLI1 mRNA expression anal-
ysis in a set of normal human mammary epithelial cell
lines in comparison to malignant human mammary cell
lines by semiquantitative realtime PCR (Figure 1). Com-
pared to the primary cell line HMEC (human mammary
epithelial cells) and the immortalised benign cell line
MCF12A, GLI1 expression was clearly upregulated in the
analysed set of breast cancer cell lines. However, the
immortalised benign cell line MCF10A also demonstrates
abundant GLI1 expression. Differences were statistically
not significant (P = 0.414, two-tailed Mann-Whitney U-
test).
GLI1 mRNA expression in primary breast cancers
Next we analysed GLI1  mRNA expression in a set of
matched tumour and normal breast tissue samples (n = 5;
Figure 2). Four of five analysed matched samples exhib-
ited increased levels of GLI1  mRNA expression in the
tumourous breast tissues compared to their adjacent nor-
mal tissues. However overexpression of GLI1 in the ana-
lysed breast tumours was statistically not significant (P =
0.251, two-tailed Mann-Whitney U-test).
GLI1 protein expression analysed on the breast cancer 
TMA
Next, GLI1 protein expression and localisation was stud-
ied on a large TMA including normal (n  = 46) and
Elevated expression of GLI1 mRNA in breast cancer cell lines Figure 1
Elevated expression of GLI1 mRNA in breast cancer 
cell lines. Semiquantitative realtime PCR (Light Cycler) anal-
ysis for GLI1 expression was performed on reverse tran-
scribed RNA extracted from non-malignant (grey bars) and 
malignant breast cell lines (black bars). Expression data were 
related to GLI1 mRNA expression in the human mammary 
epithelial cell line HMEC (set to 1). In five of eight analysed 
malignant mammary cell lines (SKBR3, MDA-MB468, BT20, 
MDA-MB231 and MDA-MB435s) increased levels of GLI1 
mRNA expression were found. GLI1 mRNA expression in 
normal human epithelial mammary cell lines HMEC and 
MCF12A cells is relatively low, except for cell line MCF10A 
which also presents abundant GLI1 expression.BMC Cancer 2009, 9:298 http://www.biomedcentral.com/1471-2407/9/298
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tumourous breast tissues (n = 204). Immunohistochemi-
cal stainings were processed using a primary GLI1 anti-
body (Santa Cruz sc-20687) that has been verified for
specificity as described previously [26,27]. GLI1 immuno-
histochemical staining was detectable in both the cyto-
plasm and the nucleus of benign and malignant
mammary epithelial cells. However, nuclear expression
was more abundant (Figure 3), and as GLI1 is a transcrip-
tion factor, nuclear GLI1 expression was scored for subse-
quent data analyses and correlation studies. Considering
the whole TMA 97% (198/204) of the analysed breast car-
cinomas and 76% (35/46) of all analysed normal breast
tissues were shown to present abundant nuclear GLI1 pro-
tein expression. In the nucleus of normal breast tissues,
GLI1 protein expression was less abundant (median IRS =
6) than in the nucleus of breast carcinoma cells (median
IRS = 8) (P = 0.008, two-tailed Mann-Whitney U-test).
Intensities of nuclear GLI1 protein varied strongly
between the different breast tumours as IRS values
detected on the TMA ranged between 2 and 12 (3.1% and
24.6% of all analysed tumours, respectively).
Figure 3 demonstrates nuclear GLI1 expression in normal
breast tissues (A and B), ductal carcinomas in situ of high
grade type (C and D) and in invasive breast carcinomas of
ductal type (E and F). Ductal carcinomas in situ and inva-
sive breast tumours are both characterised by abundant
nuclear GLI1 expression.
Correlation analysis including clinicopathological 
parameters
GLI1 acts as a transcription factor mediating Hh signalling
in embryonic and adult cells. For correlation analysis of
nuclear GLI1 expression and clinicopathological data we
performed an easy stratification of GLI1 expression in
"low expressers" (IRS score 0 to 6) and "high expressers"
(IRS score 7 to 12). A significant correlation was found
between increased expression of nuclear GLI1 and tumour
stage (P < 0.001) but also between increased expression of
nuclear GLI1 and the lymph node status (P = 0.027) of the
analysed tumours (Table 3). No significant association
was found between GLI1 expression and the presence of
HER2 receptor (P = 0.484), oestrogen receptor (P = 0.266)
or progesterone receptor (P = 0.847) (Table 3).
GLI1 overexpression correlates with unfavourable patient 
prognosis
To answer the question whether GLI1 overexpression
might have an impact on patients' clinical outcome uni-
variate survival probability curves were calculated based
on the immunohistochemical results. Using Kaplan-Meier
analysis we found that "high GLI1 expressers" (IRS 7–12)
had an unfavourable overall survival prognosis (P  =
0.019) (Table 4, Figure 4). Regarding the clinical impact
of increased GLI1 protein expression on breast tumour
recurrence the derived data were statistically not signifi-
cant (P = 0.102; Table 4).
Logistic regression analysis including tumour stage (pT), 
lymph node status (pN) and histological grade (G)
Multivariate logistic regression analysis was carried out to
evaluate the role of tumour stage, histological grade and
lymph node status as indicators for GLI1 overexpression
(Table 5). The odds for GLI1 overexpression (IRS 0–6 vs
IRS 7–12) increased 4.9 times (95% CI 2.3 – 10.5) in
patients with pT2 compared to those with pT1 (P  <
0.001). However regression analysis including the
remaining pT stages (pT2 vs pT3 and pT3 vs pT4), pN sta-
tus (pN0 vs pN1-3) and tumour grade (G0 vs G1-3) failed
significance as independent prognostic indicators of GLI1
overexpression.
SHH protein expression in correlation to GLI1 expression 
data
Previously we have analysed SHH expression on the same
breast cancer TMA (ten Haaf et al. (2009), submitted).
Since GLI1 is supposed to be a direct downstream target of
Hh signalling in model organisms like Drosophila [28]
we wanted to decipher whether there is a correlation
between the SHH and GLI1 expression patterns in human
breast cancer and normal human breast tissues. Indeed,
we found a highly significant positive correlation between
the expression data of these two Hh signalling members.
(Table 6; P < 0.001 in both tested correlation combina-
tions).
Discussion
GLI1, a mediator of the Hh signalling pathway has previ-
ously been implicated in the development of different
human tumour entities such as oesophageal squamous
GLI1 expression in primary breast cancer Figure 2
GLI1 expression in primary breast cancer. Realtime 
PCR analysis of GLI1 mRNA expression in a set of five 
matched pairs (N = normal vs. T = tumour) revealed 
increased levels of GLI1 expression in tumourous tissue for 
four of the five analysed matched pairs. Expression level of 
each sample is normalised to its GAPDH expression and 
related to normal breast tissue (N1) (set to 1).BMC Cancer 2009, 9:298 http://www.biomedcentral.com/1471-2407/9/298
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Immunohistochemical expression analysis of GLI1 protein in normal breast tissue, non-invasive and invasive breast tumours  using a TMA Figure 3
Immunohistochemical expression analysis of GLI1 protein in normal breast tissue, non-invasive and invasive 
breast tumours using a TMA. (A, B) In normal breast tissue low levels of GLI1 expression are detectable in the cytoplasm 
(median IRS = 4) and in the nucleus (median IRS = 6). In ductal carcinomas in situ of high grade type (C, D) as well as in invasive 
breast carcinomas (E, F) nuclear GLI1 expression is more intense than in normal breast tissues (median IRS = 8), whereas the 
cytoplasmic GLI1 expression is weak (median IRS = 3). (G, H) Representative tissue section from human basal cell carcinoma 
which served as a positive control for GLI1 staining. (I, J) Negative control – benign breast tissue. Magnifications: A, C, E, G, I: 
100×; B, D, F, H, J: 400×.BMC Cancer 2009, 9:298 http://www.biomedcentral.com/1471-2407/9/298
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cell carcinomas [16], basal cell carcinomas [29] and brain
tumours [30]. Consistent with a major role in carcinogen-
esis highly increased levels of GLI1 expression were found
in basal cell carcinomas but not in the surrounding nor-
mal breast tissues [15,29,31].
To analyse the role of GLI1 in human breast cancer we car-
ried out an initial realtime PCR analysis and found
increased levels of GLI1 mRNA expression comparing the
malignant mammary cell lines SKBR3, MDA-MB468,
BT20, MDA-MB231 and MDA-MB435s to a set of benign
mammary cell lines (HMEC and MCF12A). GLI1 mRNA
was especially abundant in the cell line MDA-MB435s,
which is a common in vitro and in vivo model for meta-
static breast cancer behaviour [32] stating a potential
involvement of GLI1 signalling in human breast tumour
metastasis. Interestingly we also detected high levels of
GLI1 mRNA expression in the benign breast cell line
MCF10A.
It is known that GLI proteins themselves are mediators of
more than just the Hh signalling pathway [12] and over-
expression of GLI1 is reported from several human
tumour entities [16,29,30] as well as benign tissues of
organs like prostate or colon [33,34]. Therefore a func-
tional involvement of GLI1 activity in human tumour
development [35] but also within cellular processes and
maintenance of normal adult tissues might be concluded
[33]. mRNA expression analysis was further applied to a
set of five matched normal and tumourous breast tissues.
The results from these analyses underlined a potential
involvement of GLI1 as a transcriptional regulator impor-
tant for breast cancer development as increased levels of
GLI1 expression were shown in four out of five analysed
samples. However data derived from these studies were
statistically not significant maybe because of the small
sample numbers. Therefore accuracy of this first explora-
tive approach should be tested in a larger validation set.
Table 3: Clinicopathological and immunohistochemical parameters in relation to nuclear GLI1 immunoreactivity
Variable Categorization GLI1 nuclear immunoreactivityb 0–6 vs 7–12
n analyzable low high Pc
Clinicopathological data:
Tumour stagea
pT1 57 34 23 <0.001
pT2 87 19 68
pT3 12 3 9
pT4 28 8 20
Lymph node status
pN0 78 36 42 0.027
pN1-3 100 30 70
Histologic grade
G1 21 10 11 0.191
G2 81 29 52
G3 82 25 57
Multifocality
unifocal tumour 161 57 104 0.844
multifocal tumour 24 8 16
Histologic type
ductal 152 57 95 0.312
lobular 14 3 11
other 17 5 2
Immunohistochemistry (IHC):
Oestrogen receptor status
negative 53 19 34 0.484
positive 96 29 67
Progesterone receptor status
negative 109 33 76 0.266
positive 51 20 31
HER2 status
weak (0–2+) 132 45 87 0.847
strong (3+) 31 10 21
aAccording to UICC: TNM Classification of Malignant Tumours. 6th edn (2002) Sobin LH, Wittekind CH (eds) Wiley: New York
bGLI1 nuclear immunoreactivity: low = IRS 0–6, high = IRS 7–12
cFisher's exact test (two-sided), bold face representing significant data (P < 0.05)BMC Cancer 2009, 9:298 http://www.biomedcentral.com/1471-2407/9/298
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GLI1 expression was also studied on protein level using a
larger cohort of human breast cancers (n = 204) as well as
normal breast tissues (n = 46). We were able to show sig-
nificantly increased levels of nuclear GLI1 protein expres-
sion (median IRS = 8) in human breast carcinomas in
comparison to normal breast tissues (median IRS = 6).
Furthermore intensities of GLI1 expression varied strongly
between the different analysed tissues. These data are in
accordance to earlier findings from Kubo et al. (2004)
where nuclear GLI1 overexpression was found in a set of
human breast cancers (n = 52) and ratios of GLI1 express-
ing carcinoma cells varied strongly between the different
breast tumour samples [35]. Thus overexpression of GLI1
may not be a general characteristic of all human breast
cancers although it could be a useful marker for a subset
of human breast tumours, what we will analyse in more
detail in our upcoming studies.
Analysing the data from our TMA a positive significant
association was found between overexpression of GLI1
and unfavourable overall survival outcome. This associa-
tion has not been reported anywhere else so far, but simi-
lar tendencies were recently shown in human oesophageal
cancer [36]. Patients with abundant GLI1 expression in
the tumour (IRS > 6) had an estimated mean OS of 117
months (95% confidence interval [CI]: 105 to 125
months) compared to an estimated mean OS of 102
months (95% CI: 91 to 112 months) which was found in
patients with lower levels of GLI1 expression (IRS = 6).
Our data indicate that nuclear GLI1 overexpression being
associated with unfavourable overall survival could be a
phenomena found in a variety of human solid tumours
that have been shown to express members of the Hh sig-
nalling pathway [2,5,6,8,37].
To assess the role of GLI1 for the progression of human
breast cancer in more detail we next correlated GLI1
expression data to clinicopathological characteristics of
the tumours. Interestingly we found a positive significant
association between increased nuclear GLI1 expression
Table 4: Univariate analysis of factors regarding overall survival (OS) and recurrence-free survival (RFS)
Variable Categorization Tumour-related death (OS) Tumour recurrence (RFS)
ne v e n t s Pb ne v e n t s Pb
Clinicopathological data:
Tumour stagea
low (pT 0–1) 58 10 0.001 56 12 0.000
high (pT 2–4) 128 54 123 64
Lymph node status
negative (pN 0) 78 12 0.000 77 14 0.000
positive (pN 1–3) 101 46 98 57
Histologic grade
low (G 1–2) 102 26 0.001 97 30 0.000
high (G 3) 83 38 81 45
Multifocality
unifocal tumour 162 53 0.164 157 65 0.453
multifocal tumour 24 11 22 11
Histologic type
ductal 152 51 0.614 149 65 0.562
lobular 14 7 12 5
other 18 6 16 5
Immunohistochemistry (IHC):
Oestrogen receptor status
negative (IRS 0–2) 84 35 0.006 83 39 0.055
positive (IRS 3–12) 66 14 63 20
Progesterone receptor status
negative (IRS 0–2) 51 7 0.000 104 51 0.004
positive (IRS 3–12) 110 48 51 12
HER2 IHC
weak (0–2+) 126 48 0.044 133 38 0.014
strong (3+) 31 17 31 15
GLI1c
low (IRS 0–6) 66 15 0.019 64 23 0.102
high (IRS 7–12) 120 49 116 53
aAccording to UICC: TNM classification of malignant tumours. 6th edn (2002) Sobin LH, Wittekind CH (eds) Wiley: New York
bLog rank test (two-sided), bold face representing significant data (P < 0.05)
cGLI1 nuclear immunoreactivity: low = IRS 0–6, high = IRS 7–12BMC Cancer 2009, 9:298 http://www.biomedcentral.com/1471-2407/9/298
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and tumour stage, lymph node status of the analysed
breast tumours supporting a role of GLI1 as a new prog-
nostic marker. We also carried out multivariate analysis
and found a significant association between advanced
tumour stage (pT2 vs pT1) and increased likelihood of
GLI1 overexpression in the analysed tumours (4.9 times;
95% CI 2.3 – 10.5). However associations between GLI1
overexpression and lymph node status as well as histolog-
ical grade of the tumours as stated by univariate analysis
were multivariate insignificant.
Similar to our study Kubo et al. (2004) correlated expres-
sion of GLI1 to clinicopathological characteristics of
human breast tumours and found a significant associa-
tion of GLI1 overexpression to oestrogen receptor status
and histological subtype of the analysed tumours (P =
0.0216 and P = 0.0036) [35]. These correlations could not
be stated through the results from our study and therefore
we would not support the hypothesis of an involvement
of the Hh pathway in the hormone-induced development
of human breast carcinomas [35,38].
With lower abundance (median IRS = 6) GLI1 was also
expressed in the nucleus of normal breast cells, and there-
fore we suggest a general involvement of GLI1 in tran-
scriptional regulatory processes that are not only
important within tumour development but also in nor-
mal breast cells. However Kubo et al. analysed normal
breast epithelia (n = 52) and did not detect GLI1 expres-
sion in the nucleus of normal breast cells adjoining the
analysed tumourous tissues.
So far the discrepancies between these two studies remain
unsolved and should therefore be topic of further analyses
characterizing the potential of GLI1 as a new potential
prognostic marker of human breast cancer.
To find out more about the complexity of GLI1 signalling
and its functional implications on human breast cancer a
systematic characterisation of potential upstream and
downstream targets of GLI1 in tumourous breast samples
that are characterised by GLI1 overexpression would be an
important approach. Interestingly the results from our sta-
tistical analyses showed a significant association between
GLI1 overexpression and the presence of Hh member
SHH in human breast tumours. Our observations indicate
that not only GLI1 expression but more important its
implication in the Hh signalling pathway might be a more
precise characteristic of human breast cancers.
SHH and GLI are both members of the Hh signalling cas-
cade which was first described in the fruit fly Drosophila
[39] and it might be reasonable to assume that this signal-
ling pathway is conserved and active in a proportion of
human breast cancers. In mammals, a direct influence of
SHH expression on increased GLI1 activity has been
described in a variety of biological processes, e.g. during
mouse limb bud development [40]. Furthermore
Breast cancer patients expressing nuclear GLI1 protein show  unfavourable prognosis Figure 4
Breast cancer patients expressing nuclear GLI1 pro-
tein show unfavourable prognosis. Univariate Kaplan-
Meier analysis was performed on the basis of GLI1 expres-
sion results derived from the TMA. Patients with low GLI1 
expression (IRS = 0–6) displayed improved overall survival 
estimation (upper graph) compared to patients with abun-
dant nuclear GLI1 expression (IRS 6–12; lower graph) (P = 
0.019; univariate log-rank analysis).
Table 5: Logistic regression analysis for tumour stage, lymph node status and histological grading and GLI1 immunohistochemistry
Characteristic P-value Odds ratio 95.0% confidence interval (CI)
pTa (pT1 vs pT2) 0.000 4.911 [2.297–10.501]
pTa (pT2 vs pT3) 0.078 3.782 [0.862–16.599]
pTa (pT3 vs pT4) 0.083 2.673 [0.881–8.113]
pNa (pN0 vs pN1-3) 0.383 1.400 [0.658–2.979]
G (G0 vs G1-3) 0.280 1.779 [0.625–5.065]
Abbreviations: pT, tumour stage; pN, lymph node status; G, histological grading.
Significant P-values marked inbold face.
aAccording to UICC: TNM classification by Sobin and Wittekind (2002).BMC Cancer 2009, 9:298 http://www.biomedcentral.com/1471-2407/9/298
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increased expression of SHH mRNA in human colonic
adenocarcinomas is known to correlate with downstream
increased expression of GLI1 leading to promotion of cell
proliferation [41]. In human cancer, sustained activity of
Hh-GLI signalling is indicated to be essential in growth
and survival of human prostate cancer cells [42]. The
results from our correlation analyses between SHH and
GLI1 are in accordance to these findings and may lead to
the suggestion that GLI1 activity is mediated through the
Hh initiating molecule SHH and that abundant levels of
nuclear GLI1 expression observed in breast cancer could
be a result of increased SHH activity. More interestingly
Hh signalling is also active in human breast cancer stem
cells and studies on in vitro culture systems showed that an
activation of this pathway with Hh ligands promotes the
self-renewal of mammary stem cells, and also increases
proliferation of mammary progenitor cells as reflected by
increased numbers of mammosphere-initiating cells and
increased mammosphere size [43]. On regard of this an
early oncogenic activation of Hh signalling as an initial
step in breast cancer development starting at the level of
tumour progenitor stem cells could be proposed.
To achieve therapeutic benefits of new oncogenic markers
that are involved into tumour development, strategies
have to be developed to inhibit their cancer initiating
potential. Interestingly a number of molecules inhibiting
the Hh signalling pathway have already been described.
Cyclopamine for example is an inhibitory molecule for
Hh signalling and has been shown to inhibit the prolifer-
ation of brain tumour cells which contain an active Hh
signalling pathway [44]. GANT61 a hexahydropyrimidine
derivative and GANT58 possessing a thiophene core with
four pyridine rings, are two other small-molecule antago-
nists, which act in the nucleus to block GLI1 function and
inhibit GLI1 mediated transcription [45]. Assuming that
GLI1 might be involved into human breast cancer devel-
opment and further proposing that GLI1 is activated
through upstream members of the Hh signalling cascade,
the mentioned Hh inhibitors could offer new drugs in the
treatment of breast cancer as well.
In conclusion, we showed nuclear GLI1 overexpression in
human breast carcinomas relative to normal breast tissue
on the RNA and protein level. Interestingly, we also found
a significant positive correlation between increased
nuclear GLI1 expression and aggressive tumour character-
istics (i.e. tumour stage and lymph node status). The
aggressive behaviour of GLI1 positive breast cancers is
supported by the finding that GLI1 overexpression is asso-
ciated to unfavourable overall survival.
Our data raise the hypothesis that GLI1 represents a can-
didate oncogene in human breast cancer. Additional stud-
ies validating these data and further analysing possible
interactions of GLI1 with other Hh signalling members
are underway to clarify the role of this important develop-
mental pathway for the pathogenesis of human breast
cancer.
Conclusion
GLI1 is an important transcriptional regulator within the
Hh signalling cascade and may represent a novel biomar-
ker in the development of human breast cancer with pos-
sible applications for future multimarker panels for early
detection, molecular sub typing or personalised treat-
ment. Increased levels of nuclear GLI1 expression in
human tumourous breast tissues show a significant asso-
ciation towards lower overall survival outcome and a
more aggressive tumour phenotype. Further studies will
be conducted to validate overexpression of GLI1 in
human breast tumours also on mRNA level and gain more
insight into the relevance of Hh signalling for human
breast cancer development.
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